PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with … LS Schwartzberg, F Rivera, M Karthaus, G Fasola, JL Canon, JR Hecht, ... Journal of clinical oncology 32 (21), 2240-2247, 2014 | 770 | 2014 |
Measures of outcome in metastatic breast cancer: insights from a real-world scenario M Bonotto, L Gerratana, E Poletto, P Driol, M Giangreco, S Russo, ... The oncologist 19 (6), 608-615, 2014 | 269 | 2014 |
Clinical advances in the development of novel VEGFR2 inhibitors C Fontanella, E Ongaro, S Bolzonello, M Guardascione, G Fasola, ... Annals of translational medicine 2 (12), 2014 | 266 | 2014 |
Pattern of metastasis and outcome in patients with breast cancer L Gerratana, V Fanotto, M Bonotto, S Bolzonello, AM Minisini, G Fasola, ... Clinical & experimental metastasis 32, 125-133, 2015 | 204 | 2015 |
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection M Schirripa, F Bergamo, C Cremolini, M Casagrande, S Lonardi, G Aprile, ... British journal of cancer 112 (12), 1921-1928, 2015 | 175 | 2015 |
Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B F Menichetti, A Del Favero, P Martino, G Bucaneve, A Micozzi, ... Annals of internal medicine 120 (11), 913-918, 1994 | 171 | 1994 |
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 … F Leone, D Marino, S Cereda, R Filippi, C Belli, R Spadi, G Nasti, ... Cancer 122 (4), 574-581, 2016 | 135 | 2016 |
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients … F Rivera, M Karthaus, JR Hecht, I Sevilla, F Forget, G Fasola, JL Canon, ... International journal of colorectal disease 32, 1179-1190, 2017 | 125 | 2017 |
Expression of periostin in human breast cancer F Puglisi, C Puppin, E Pegolo, C Andreetta, G Pascoletti, F D’Aurizio, ... Journal of clinical pathology 61 (4), 494-498, 2008 | 111 | 2008 |
Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach F Grossi, M Aita, C Defferrari, F Rosetti, A Brianti, G Fasola, O Vinante, ... The oncologist 14 (5), 497-510, 2009 | 101 | 2009 |
Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility … G Fasola, O Belvedere, M Aita, T Zanin, A Follador, P Cassetti, S Meduri, ... The oncologist 12 (10), 1215-1224, 2007 | 100 | 2007 |
Italian nivolumab expanded access program in nonsquamous non–small cell lung cancer patients: results in never-smokers and EGFR-mutant patients MC Garassino, AJ Gelibter, F Grossi, R Chiari, HS Parra, S Cascinu, ... Journal of Thoracic Oncology 13 (8), 1146-1155, 2018 | 85 | 2018 |
Drug waste minimization as an effective strategy of cost-containment in oncology G Fasola, G Aprile, L Marini, A Follador, M Mansutti, M Miscoria BMC health services research 14, 1-7, 2014 | 84 | 2014 |
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer L Fornaro, S Cereda, G Aprile, S Di Girolamo, D Santini, N Silvestris, ... British journal of cancer 110 (9), 2165-2169, 2014 | 83 | 2014 |
Drug waste minimisation and cost-containment in medical oncology: two-year results of a feasibility study G Fasola, M Aita, L Marini, A Follador, M Tosolini, L Mattioni, M Mansutti, ... BMC Health Services Research 8, 1-8, 2008 | 80 | 2008 |
Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer L Foltran, GD Maglio, N Pella, P Ermacora, G Aprile, E Masiero, ... Future Oncology 11 (4), 629-640, 2015 | 78 | 2015 |
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme U De Giorgi, G Cartenì, D Giannarelli, U Basso, L Galli, E Cortesi, ... BJU international 123 (1), 98-105, 2019 | 77 | 2019 |
The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients D Basile, A Parnofiello, MG Vitale, F Cortiula, L Gerratana, V Fanotto, ... Journal of cachexia, sarcopenia and muscle 10 (2), 368-377, 2019 | 74 | 2019 |
Molecular classifications of gastric cancers: Novel insights and possible future applications SK Garattini, D Basile, M Cattaneo, V Fanotto, E Ongaro, M Bonotto, ... World journal of gastrointestinal oncology 9 (5), 194, 2017 | 68 | 2017 |
Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with or without adjuvant chemotherapy in patients with resected stage IB to III MAGE-A3-positive non-small-cell … JL Pujol, JF Vansteenkiste, TM De Pas, D Atanackovic, M Reck, ... Journal of Thoracic Oncology 10 (10), 1458-1467, 2015 | 63 | 2015 |